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BACKGROUND: The conventional treatment options for advanced gastric patients remain unsatisfactory in terms of response rate,
response duration, toxicity, and overall survival benefit. The purpose of this phase II study was to evaluate the activity and safety of
cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction
adenocarcinoma.
METHODS: Untreated patients with histologically confirmed advanced gastric or gastro-oesophageal adenocarcinoma received
cetuximab at an initial dose of 400mgm2 i.v. followed by weekly doses of 250mgm2, cisplatin 75mgm2 i.v. on day 1, docetaxel
75mgm2 i.v. on day 1, every 3 weeks, for a maximum of 6 cycles, and then cetuximab maintenance treatment was allowed in
patients with a complete response, partial response, or stable disease.
RESULTS: Seventy-two patients (stomach 81.9% and gastro-oesophageal junction 18.1%; locally advanced disease 4.2%; and metastatic
disease 95.8%) were enrolled. The ORR was 41.2% (95% CI, 29.5–52.9). Median time to progression was 5 months (95% CI,
3.7–5.4). Median survival time was 9 months (95% CI, 7–11). The most frequent grades 3–4 toxicity was neutropenia (44.4%).
No toxic death was observed.
CONCLUSIONS: The addition of cetuximab to the cisplatin/docetaxel regimen improved the ORR of the cisplatin/docetaxel doublet in
the first-line treatment of advanced gastric and gastro-oesophageal junction adenocarcinoma, but this combination did not improve
the TTP and OS. The toxicity of cisplatin/docetaxel chemotherapy was not affected by the addition of cetuximab.
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Gastric cancer is a considerable health problem worldwide and as
such remains a major challenge for the whole oncology commu-
nity. For the year 2007, gastric cancer was estimated to be the
second leading cause of cancer death among men and the fourth
among women, with an expectancy of 800 000 cancer-related
deaths overall (Parkin et al, 2005). There is remarkable geographic
variation, with 60% of cases arising in Eastern Asia (Kelley and
Duggan, 2003; Parkin et al, 2005; Garcia et al, 2007). In the
European Union, for the year 2002, the number of deaths from
gastric cancer was 40 759 among men and 27 980 among women
(Bosetti et al, 2008). In the same year, in Italy, stomach cancers
accounted for 6.7% of cancer deaths in both sexes with 6266 deaths
in men and 4686 in women (Malvezzi et al, 2008). Although the
incidence of gastric cancer is declining in the Western world,
adenocarcinomas of the gastro-oesophageal junction (GEJ) are
increasing in number (Kelley and Duggan, 2003; Parkin et al, 2005;
Garcia et al, 2007; Bosetti et al, 2008; Malvezzi et al, 2008).
In patients with resectable cancer, surgery and perioperative
therapy are potentially curative treatments. However, the majority
of patients with gastric cancer had stage III or IV disease at
presentation and thus are candidates for palliative chemotherapy.
In advanced disease, the median survival in patients not receiving
chemotherapy is 3–4 months. A systematic meta-analysis of
randomised studies found a statistically significant advantage of
chemotherapy compared with the best supportive care and
combination of three-drug regimens containing 5-fluorouracil,
anthracyclines, and cisplatin (Wagner et al, 2006). New triplet and
doublet combinations incorporating docetaxel, oxaliplatin, irino-
tecan, capecitabine, and S-1 have been evaluated in randomised
trials. Although little progress has been made in these trials
towards improving the median overall survival time beyond 9
months, the outcome of advanced disease is still disappointing
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(Van Cutsem et al, 2006; Cunningham et al, 2008; Dank et al, 2008;
Koizumi et al, 2008; Ajani et al, 2009; Kang et al, 2009).
The conventional treatment options for advanced gastric
patients remain unsatisfactory in terms of response rate, response
duration, toxicity, and overall survival benefit. Targeted agents are
therefore being investigated in an effort to improve the clinical
outcome of gastric cancer patients.
The epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein that is a member of the tyrosine kinase growth
factor receptor superfamily. The EGFR represents an important
therapeutic target in cancer. The EGFR is expressed in many
normal human tissues and has been found to be overexpressed in a
large variety of tumours (Ciardiello and Tortora, 2001). In gastric
cancer, EGFR is overexpressed in 18–91% of primary tumours
and/or metastasis and correlated with a poor prognosis (Tokunaga
et al, 1995; Albanell et al, 2001; Mendelsohn, 2002; Takehana
et al, 2003; Pinto et al, 2007). Cetuximab (Erbitux, Merck KgaA,
Darmstadt, Germany) is a human-murine chimeric monoclonal
antibody directed to the EGFR binding site. Cetuximab in
metastatic colorectal cancer added to standard chemotherapy
produces an improvement in the response rate in randomised
studies in both a first-line setting and in patients with refractory
disease (Cunningham et al, 2004; Sobrero et al, 2008; Bokemeyer
et al, 2009; Van Cutsem et al, 2009). Cetuximab in combination
with chemotherapy regimens containing irinotecan (Pinto et al,
2007; Kanzler et al, 2009), oxaliplatin (Lordick et al, 2007; Han
et al, 2008, 2009), and cisplatin (Zhang et al, 2008; Yeh et al, 2009)
as first-line therapy of advanced gastric or GEJ adenocarcinoma
has also shown promising results.
The docetaxel and cisplatin (DC) combination is an active
regimen in advanced gastric cancer patients, and it yielded a
response rate of 18.5–26% in two randomised phase II studies
(Ajani et al, 2005; Roth et al, 2007). In preclinical studies,
cetuximab enhances the activity of cisplatin (Steiner et al, 2007)
and docetaxel (Nakata et al, 2004). Given these data, this phase II
study was performed to evaluate the efficacy and toxicity of a
regimen combining a targeted therapy, cetuximab with cisplatin
and docetaxel chemotherapy, for unresectable locally advanced or
metastatic gastric and GEJ adenocarcinoma.
PATIENTS AND METHODS
Study design
We conducted a multicentre phase II study that was approved by
the local ethics committee, registered with the health authorities,
and performed according to the guidelines of good clinical practice
and the Declaration of Helsinki. The primary end point was
objective response (ORR). Secondary end points were toxicity,
median survival time (OS), and time to progression (TTP).
Patient and treatment
Patients with advanced, unresectable, histologically confirmed
adenocarcinoma of the stomach or GEJ were assessed for
eligibility. The eligibility criteria were: age X18 years, Karnofsky
performance status (KPS) X70, life expectancy 43 months, no
earlier treatment with chemotherapy or radiation therapy,
neutrophil count X1500 per ml, platelet count X100.000 per ml,
haemoglobin X9.0 g dl1, serum creatinine p1.5 upper limit of
normal (ULN), ALT and AST p2.5ULN (p5ULN in the
presence of liver metastases), total bilirubinp1.5ULN, measur-
able disease according to the Response Evaluation Criteria in Solid
Tumours (RECIST) (Therasse et al, 2000). Prior chemotherapy for
advanced cancer was not allowed. Patients who received adjuvant
therapy were eligible provided more than 6 months had elapsed
between the end of adjuvant therapy and registration for the study.
All the patients provided written informed consent for this study,
which was approved by the ethics committee of each participating
institution. Patients were considered ineligible for the trial if they
satisfied any of the following criteria: previous exposure to anti-
EGFR, monoclonal antibodies, signal transduction inhibitors, or
EGFR targeting therapy; brain metastasis; concurrent malignancy
other than non-melanoma skin cancer, or in situ cervix carcinoma
(patients with an earlier malignancy but with no evidence of
disease for 45 years were allowed to enter the trial); clinically
relevant coronary artery disease or a history of myocardial
infarction within the last 12 months; acute or subacute intestinal
occlusion or history of the inflammatory bowel disease; pre-
existing neuropathy; known grade 3 or 4 allergic reaction to any of
the components of the treatment; pregnancy or lactating status;
medical or psychological condition which, in the investigator’s
opinion, would not enable the patient to complete the study or
knowingly sign the informed consent.
The baseline evaluation included a history, physical examination
(including evaluation of vital signs and performance status),
recording of concomitant medication, laboratory tests (haemato-
logy and clinical chemistry, CEA, CA19.9, CA 72.4), thorax and
abdomen computed tomography or magnetic resonance imaging,
and positron emission tomography scan.
In a collateral study, the KRAS and BRAF mutational status was
evaluated. Genomic DNA was extracted from paraffin-embedded
primary tumour specimens. The mutational status of KRAS
(exon 2) and BRAF (exon 15) was ascertained by PCR amplifica-
tion followed by direct sequencing.
The phase I study was not performed as no significant increase
of chemotherapy toxicity was reported in the earlier phase II
studies with cetuximab added to the chemotherapy regimens
(Lordick et al, 2007; Pinto et al, 2007; Han et al, 2008; Zhang et al,
2008; Han et al, 2009; Yeh et al, 2009; Kanzler et al, 2009).
Patients received cetuximab at an initial dose of 400mgm2 i.v.
followed by weekly doses of 250mgm2, cisplatin 75mgm2 i.v.
(1-h infusion) plus docetaxel 75mgm2 i.v. (1-h infusion) on day 1
every 3 weeks, for a maximum of 6 cycles, and then cetuximab
alone was allowed in patients with complete response, partial
response, and stable disease (maintenance therapy). Cetuximab
premedication comprised antihistamine and corticosteroids i.v. All
patients received the following supportive medications: 3 l per day
hyperhydration; dexamethasone 8mg (or equivalent drugs) orally
administered 12 and 6 h before docetaxel infusion and 8mg orally
twice daily for 4 days after infusion; 5-hydroxytryptamine-
3-inhibitors as emesis prophylaxis. In patients benefiting from
combination therapy but developing unacceptable intolerance/
toxicity to cetuximab or cisplatin/docetaxel, cisplatin/docetaxel or
cetuximab may be continued as a single treatment and vice-versa.
Surgery of locally advanced gastric cancer could be performed
during the study at the time of maximum regression under the
earlier assessment of the tumour response after at least 12 weeks of
treatment (at least 2 cycles of cisplatin/docetaxel plus cetuximab).
If a complete resection was achieved, patients would restart the
treatment up to a maximum of 6 treatment cycles (adding pre- and
post-surgery treatment).
If a patient experiences grade 3 skin toxicity, cetuximab therapy
may be deferred for up to two consecutive infusions without
changing the dose level. If the toxicity resolves to grade 2 or less by
the following treatment period, the treatment may resume. With
the second and third occurrences of grade 3 skin toxicity,
cetuximab therapy may again be deferred for up to two
consecutive weeks with concomitant dose reductions to 200 and
150mgm2, respectively. Patients should discontinue cetuximab if
more than two consecutive infusions are withheld or a fourth
occurrence of grade 3 skin toxicity occurs despite an appropriate
dose reduction. Chemotherapy was continued independently of a
temporary interruption of cetuximab. Cetuximab was not withheld
for cisplatin/docetaxel-related toxicity. Cisplatin/docetaxel dose
Cetuximab in combination with cisplatin and docetaxel
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reduction was planned in the event of severe haematological and/
or non-haematological toxicities. Treatment could be delayed for
up to 2 weeks to allow toxicities to resolve; delays of 42 weeks
required treatment withdrawal. A 15mgm2 dose reduction of
docetaxel or cisplatin was planned for prolonged (47 days) grade
4 neutropenia, or thrombocytopenia, grade X2 liver toxicity. For
grade 2 neurotoxicity, the DC doses were reduced by 15mgm2.
Cisplatin was reduced or discontinued if creatinine clearance was
o60 or o40mlmin1. Treatment was discontinued for persistent
grade 3 liver toxicity, anaphylaxis, or fluid retention; grade X3
neuropathy; or a recurrent toxicity despite dose reductions.
Response and toxicity
Routine evaluation of patients was performed on a weekly basis
during therapy. These evaluations included a physical examina-
tion, vital signs, KPS, laboratory haematological and serum
chemistry, and the recording of adverse events.
The evaluation tumour response to therapy was based on a
computed tomography or magnetic resonance scan. Patients were
evaluable for response if they had received at least one course of
therapy. In addition, those patients who were developing rapid
tumour progression, or those who died of progressive disease
before the response evaluation, would also be considered evaluable
for response. Also, patients who discontinued treatment, or those
who died from a treatment-related toxicity before response
evaluation, were considered evaluable for response. The tumour
was evaluated every 6 weeks during the treatment and at least
every 12 weeks during the follow-up. The RECIST criteria were
used to assess the type of response (Therasse et al, 2000). Positron
emission tomography scan was performed after 3 weeks, before
the second cycle of cisplatin/docetaxel chemotherapy. Toxicity
was graded according to the National Cancer Institute Common
Toxicity Criteria (CTC) Version 3.0 (National Cancer Institute,
Common Toxicity Criteria, 2006).
Statistical analysis
The statistical design was performed according to Simon’s two-
stage design (Simon, 1989). It was expected that the new regimen
would have a targeted response rate X40%. The first stage
required at least six or more patients out of 20 to have a confirmed
partial or complete response assuming P1¼ 0.40, P0¼ 0.25, with
a¼ 0.05 and b¼ 0.2 before proceeding to the second stage. In the
second stage, 40 assessable patients could be added and if a total of
24 or more patients achieved a confirmed objective response, then
the primary end point would have been met. Seventy-two patients
were thus needed to take account of possible attrition. TTP and OS
were calculated using the Kaplan–Meier method (Kaplan and
Meier, 1958). Descriptive statistics were used for safety evaluation.
RESULTS
Patient population
From December 2007 to August 2008, 72 patients, in five Italian
centres, were enrolled. All 72 patients were evaluated for safety and
OS calculations, and 68 were assessable for response. Four patients
were not assessable for ORR because one patient with peritoneal
carcinomatosis died as a result of bowel occlusion in week 5 of
treatment; one died of gastric bleeding in week 1; one died of bowel
perforation in week 3; and 1 left the study because of renal toxicity
grade 3 after the first chemotherapy cycle.
The patient characteristics are listed in Table 1. The majority of
patients were males (66.7%), their median age being 63 years
(range, 18–75) and the median KPS 90 (range, 70–100). GEJ was
involved in 13 patients (18.1%). The histotype was intestinal
adenocarcinoma in 41 patients (56.9%) and non-intestinal
adenocarcinoma in 31 (43.1%). At the baseline of the study, three
patients (4.2%) had non-resectable locally advanced disease and 69
(95.8%) had metastatic disease. The majority of patients (76.4%)
had two or more metastases sites. Nine patients (12.5%) had
received prior adjuvant chemotherapy. Four patients had adjuvant
chemotherapy containing cisplatin.
Treatment administration
Altogether, 1049 weeks of cetuximab were administered, with a
median of 13.5 weeks (range, 1–35), and 325 cycles of cisplatin/
docetaxel, with a median of 5 cycles (range, 1–6). The median
relative dose intensity was 1.0 for cetuximab (range, 0.1–1.0), 1.0
for cisplatin (range, 0.5–1.0), and 1.0 for docetaxel (range,
0.3–1.0) (Table 2).
Table 1 Patient characteristics
No. 72
Characteristics No. %
Sex
Male 48 66.7
Female 24 33.3
Age, years
Median 63
Range 18–75
Karnofsky performance status
100 31 43.1
90 18 25
80 18 25
70 5 6.9
Primary tumour site
Stomach 59 81.9
Gastro-oesophageal junction 13 18.1
Histotype
Intestinal adenocarcinoma 41 56.9
Non-intestinal adenocarcinomaa 31 43.1
State of disease
Locally advanced 3 4.2
Metastatic 69 95.8
Prior surgery
Total/partial gastrectomy 25 34.7
Protesis/anastomosis 7 9.7
Adjuvant chemotherapy 9 12.5
5-FU/AF regimens 5 55.6
5-FU/CDDP regimens 2 22.2
5-FU/CDDP/EPI regimens 2 22.2
Site of disease
Primary 47 65.3
Lymph nodes 47 65.3
Liver 35 48.6
Peritoneum/local recurrence 26 36.1
Other 14 19.4
No. of organs involved
1 17 23.6
2 27 37.5
42 28 38.9
a24 (77.4%) with signet ring cells.
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Cetuximab was discontinued in two patients (2.8%) for grade 3
infusion-related reaction during the first administration; no
cetuximab reduction dose was performed. One patient stopped
docetaxel administration for grade 3 hypersensitivity reaction
during the first cycle. At least a one-dose reduction of cisplatin was
required in 20 patients (27.8%) and of docetaxel in 19 patients
(26.4%). Neutropenia was the most frequent reason for dose
reduction or delay.
Maintenance cetuximab therapy (after 6 cycles of cisplatin/
docetaxel plus cetuximab treatment) was performed in 16 (51.6%)
out of 31 eligible patients (31.6%). The median duration of
maintenance treatment was 10 weeks (range, 2–17).
Response
The data on the treatment response are listed in Table 3. One
patient (1.5%) achieved a complete response and 27 patients
(39.7%) achieved a partial response; the ORR was 41.2% (95% CI,
29.5–52.9). Twenty-four patients (33.3%) had stable disease and 16
patients (23.5%) had progressive disease. The disease control rate
(complete response plus partial response plus stable disease) was
76.5%. The median time to response was 6 weeks (range, 6–19).
The median duration of response was 5 months (range, 1–22
months).
The objective response was similar in both histotypes (45.9% for
intestinal adenocarcinoma and 35.5% in non-intestinal adenocar-
cinoma; P¼ 0.27). The ORR in patients with grade X2 skin
reactions after cetuximab therapy was higher, but not statistically
significantly, than the ORR in patients with o2 grade (P¼ 0.05)
(Table 4).
Two responding patients with non-resectable locally advanced
disease were submitted to surgery. One patient achieved a partial
response after 4 cycles of cisplatin/docetaxel plus cetuximab
therapy and after gastrectomy R0 received the other 2 cycles of
combination therapy and 12 weeks of maintenance cetuximab
(patient alive and disease-free after 26 months from the start of
treatment); and one submitted to gastrectomy R0 after 6 cycles of
combination therapy (patient alive and disease-free after 9 months
from the start of treatment). Another responder patient with
peritoneal metastases who submitted to gastrectomy after 6
therapy cycles has achieved a pathologic complete response
(patient alive with disease relapse 16 months after the start of
treatment).
Twenty-five (34.7%) patients received a second-line treatment:
13 with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI), 5
with etoposide, folinic acid, and 5-fluorouracil (ELF), 3 with
capecitabine, 3 with 5-fluorouracil, and 1 with epirubicin and
5-fluorouracil.
Time-to-progression and survival
The median follow-up time was 19 months (range, 6–26 months).
The median TTP was 5 months (95% CI, 3.7–5.4) (Figure 1). The
median OS time was 9 months (95% CI, 7–11) (Figure 2). In the
setting of patients with at least stable disease after 6 cycles of
cisplatin/docetaxel plus cetuximab eligible for cetuximab main-
tenance treatment, patients treated with maintenance cetuximab
(No.¼ 16) compared with no-maintenance treatment (No.¼ 15)
showed a trend for longer TTP of 9.2 months (95% CI, 8.1–10.1)
Table 3 Response rate
No. 68
Response No. %
Complete response 1 1.5
Partial response 27 39.7
Overall response rate 21 41.2
(95% CI) (29.5–52.9)
Stable disease 24 33.3
Progressive disease 16 23.5
Disease control rate 52 76.5
Table 2 Delivery of treatment
Cetuximab Cisplatin Docetaxel
No. of drug administration 1049 (weeks) 325 (cycles)
Median of weeks/cycles 13.5 5
Range 1–35 1–6
Median relative dose intensity 1.0 1.0 1.0
Range 0.1–1.0 0.5–1.0 0.3–1.0
Dose reduction, no. (%) 1 (1.4) 20 (27.8) 19 (26.4)
Drug discontinuation, no. (%)
Temporary 19 (26.4) 8 (11.1) 6 (8.3)
Definitive 2 (2.7) 0 1 (1.4)
Table 4 Response rate according to histotype and skin rash
Intestinal (no. 37) Non-intestinal (no. 31) Skin rash o2 (no. 36) Skin rash X2 (no. 32)
Response No. % No. % No. % No. %
CR 1 2.7 0 — 0 — 1 3.1
PR 16 43.2 11 35.5 11 30.6 16 50
ORR (95% CI) 17 45.9 (33.1–58.7) 11 35.5 (13.6–35.7) P¼ 0.27 11 30.6 (10.7–31.8) 17 53.1 (24.5–49.3) P¼ 0.05
SD 14 37.8 10 32.3 11 30.6 13 20.3
PD 6 16.2 10 32.3 14 38.9 2 6.2
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Figure 1 Time to progression.
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vs 6.6 (95% CI, 5.3–6.7) (P¼ 0.10), and OS of 19.8 months
(95% CI, 12.3–27.4) vs 7.7 (95% CI: 5.1–10.3) (P¼ 0.22).
Safety
All 72 patients were evaluated for toxicity (Table 5). The major
toxicity observed was haematological. Grades 3–4 neutropenia
occurred in 32 patients (44.4%). Febrile neutropenia was recorded
in 14 (19.4%) patients. Overall, non-haematological toxicities were
moderate, and severe episodes were rare. The most common
grades 3–4 non-haematological toxicities were asthenia (16.7%),
hypokalemia (12.5%), vomiting (8.3%), stomatitis (4.2%), and
diarrhoea (4.2%). Cetuximab-related hypersensivity reaction was
reported in 2 patients (2.8%). All grades of acne-like rash occurred
in 51 patients (70.8%), and grades 3–4 was observed in 12 (16.7%).
Grades 1–4 of hypomagnesemia was recorded in 20 of 32 patients
with available data (62.5%), and grades 3–4 was observed in only 1
patient (3.1%).
Eight deaths occurred within 60 days from the start of therapy:
one due to bowel occlusion, one due to bowel perforation, one due
to gastric bleeding, and five due to progression of disease. No toxic
death was observed.
Collateral studies
KRAS and BRAF mutational status was evaluated in 32 of 72
patients (44.4%). KRAS mutations were detected in 3 (9.4%) of the
tumours analysed. Two cases displayed amino acid substitutions of
codon 12 and 1 of codon 13. No BRAF mutations were found. In
this patient cohort, oncogenic activation of KRAS was not
significantly associated with the objective response.
The data of early 18F-FDG-PET assessment will be reported in a
subsequent publication.
DISCUSSION
Unresectable advanced or metastatic gastric cancer still has a poor
prognosis, with a median survival of o12 months. A recent meta-
analysis has confirmed that 5-fluorouracil-based regimens provide
superior survival in patients with advanced gastric cancer as
compared with those treated with the best supportive care (HR,
0.39; 95% CI, 0.28–0.52). This meta-analysis found a statistically
significant advantage in survival (P¼ 0.001) in favour of
combination chemotherapy compared with a single agent (HR,
0.83; 95% CI, 0.74–0.93). In addition, combination chemotherapy
regimens containing 5-fluorouracil, anthracycline, and cisplatin
were associated with a significant survival benefit when compared
with 5-fluorouracil and anthracycline regimens without cisplatin
(HR, 0.83; 95% CI, 0.76–0.91) (Wagner et al, 2006).
Recently developed new agents, such as docetaxel, irinotecan,
oxaliplatin, capecitabine, and S-1, have been investigated in phase
III clinical trials (Van Cutsem et al, 2006; Cunningham et al, 2008;
Dank et al, 2008; Koizumi et al, 2008; Ajani et al, 2009; Kang et al,
2009). Although some combinations, such as epirubicin, oxalipla-
tin, and capecitabine (EOX) in a REAL 2 study, have been shown to
be an interesting as well as effective regimen (overall survival 11.2
months; HR, 0.80; 95% CI, 0.66–0.97; P¼ 0.02, compared con ECF)
(Cunningham et al, 2008), no worldwide standard regimens have
been established.
In the three-arm SAKK42/99 phase II study, the patients as first-
line treatment of advanced gastric cancer were randomised to
receive the DC regimen (docetaxel at a dose of 85mgm2 on day 1
and cisplatin at a dose of 75mgm2 on day 1), or the DCF regimen
(docetaxel at a dose of 75mgm2, cisplatin at a dose of 75mgm2
on day 1, and 5-fluorouracil at a dose of 300mgm2 per day as
a continuous infusion on days 1–14), or the ECF regimen
(epirubicin at a dose of 50mgm2, cisplatin at a dose of 60mgm2
on day 1, and 5-fluorouracil at a dose of 200mgm2 per day as a
continuous infusion on days 1–21) every 3 weeks. In the
preliminary results on 119 patients, the ORR, TTP, and OS of
DC vs DCF vs ECF were 18.5 vs 36.6 vs 25%, 4.4 vs 7.8 vs 5.4
months, and 11 vs 10.4 vs 8.2 months, respectively. Grades 3–4
neutropenia was observed in 49% on the DC arm, 57% on the TCF
arm, and 34% on the ECF arm. Gastrointestinal grades 3–4
toxicities (diarrhoea, stomatitis) were observed in 3% on the DC
arm, 22% on the TCF arm, and 11% on the ECF arm (Roth et al,
2007).
In phase II of the V-325 study, first-line DC (docetaxel at a dose
of 85mgm2 on day 1 and cisplatin at a dose of 75mgm2 on
day 1) and DCF (docetaxel at a dose of 75mgm2, cisplatin at a
dose of 75mgm2 on day 1, and 5-fluorouracil at a dose of
750mgm2 per day as a continuous infusion on days 1–5), both
administered every 3 weeks, were compared in 158 patients with
advanced gastric or GEJ adenocarcinoma. Both regimens were
active. ORR, TTP, and OS of DC vs DCF were 26 vs 43%, 5.0 vs
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Figure 2 Overall survival.
Table 5 Toxicity
No. 72
All grades Grades 3–4
Toxicity No. % No. %
Haematological toxicity
Neutropenia 41 56.9 32 44.4
Febrile neutropenia NA — 14 19.4
Anemia 29 40.3 4 5.6
Thrombocytopenia 13 18.1 2 2.8
Non-haematological toxicity
Acne-like rash 51 70.8 12 16.7
Diarrhea 23 31.9 3 4.2
Asthenia 45 62.5 12 16.7
Stomatitis 26 36.1 3 4.2
Hypertransaminasemia 11 15.3 0 —
Hyperbilirubinemia 10 13.9 3 4.2
Vomiting 22 30.6 6 8.3
Anorexia 28 38.9 2 2.8
Nausea 35 48.6 8 11.1
Alopecia 33 45.8 NA —
Hypoacusia 1 4.2 0 —
Neurotoxicity 4 5.6 1 1.4
Hypomagnesemiaa 20 62.5 1 3.1
Hyponatremiaa 14 43.8 8 25
Hypokalemiaa 11 34.4 4 12.5
NA¼ not applicable. aData available in 32 patients.
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5.9 months, and 10.5 vs 9.6 months, respectively. The most
frequent grades 3–4 adverse events were neutropenia (87% in the
DC group vs 86% in the DCF group) and gastrointestinal toxicities
(30% in the DC group vs 56% in the DCF group) (Ajani et al, 2005).
In phase III of the V-325 trial, a total of 445 patients were
randomised and treated with DCF every 3 weeks or with CF
(cisplatin at a dose of 100mgm2 on day 1, and 5-fluorouracil at a
dose of 1000mgm2 per day as a continuous infusion on
days 1–5), every 4 weeks. All efficacy end points, TTP (primary
end point), OS, and ORR, were found to be significantly improved
in the DCF arm vs the CF arm 5.6 vs 3.7 months, (HR, 1.47; 95% CI,
1.19–1.82; Po0.001), 9.2 vs 8.6 months (HR, 1.29; 95% CI, 1.0–1.6;
P¼ 0.02), and 37 vs 25% (P¼ 0.01), respectively. DCF was associa-
ted with increased toxicity, compared with CF, especially grades 3–4
neutropenia (82.3 vs 56.8%), and febrile neutropenia (30 vs 13.5%)
(Van Cutsem et al, 2006). Following the results of V-325, several
variations of DCF have been reported with different administration
schedules, alternative platinum and fluoropyrimidine components
to try to optimise both efficacy and safety (Park et al, 2005;
Orditura et al, 2006; Lorenzen et al, 2007; Tebbutt et al, 2007).
Molecular targeting agents are another new topic in the field of
cancer therapy, and may provide a significant impact also in
gastric cancer treatment, as successful results have been observed
in colorectal cancer. An increase of EGFR protein expression in
gastric cancer appears to be related to biological aggressiveness,
although gene amplification has occurred only to a small extent
(Tokunaga et al, 1995; Albanell et al, 2001; Mendelsohn, 2002;
Takehana et al, 2003). Numerous studies have established that
gastric cancer has overexpressed many growth factors and their
receptors, including the EGF family, and numerous cytokines, such
as transforming growth factor (Zheng et al, 2004). The presence of
EGF in gastric cancer is correlated with the degree of gastric wall
invasion and lymph node metastasis. The 5-year survival of
patients with EGF-positive tumours is worse than that of
patients with EGF-negative tumours (Albanell et al, 2001;
Mendelsohn, 2002; Takehana et al, 2003). A recent study has
shown that hereditary diffuse gastric cancer-associated E-cadherin
germline missense mutations lead to increased EGFR activity
(Moutinho et al, 2008). Several phase II trials have reported on the
promising clinical activity of cetuximab in combination with
chemotherapy. The chemotherapy regimens included irinotecan
(FOLFIRI, FUFIRI), oxaliplatin (FUFOX, FOLFOX, XELOX), and
cisplatin (capecitabine/cisplatin). All chemotherapy regimens
contained a fluoropyrimidine. The ORR varied from 40 to 67%
in these phase II studies (Pinto et al, 2007; Lordick et al, 2007;
Han et al, 2008; Zhang et al, 2008; Han et al, 2009; Yeh et al, 2009;
Kanzler et al, 2009).
In the DOCETUX study, the addition of cetuximab to the DC
regimen (cisplatin and docetaxel at a dose of 75mgm2 for both
drugs) was associated with an improvement in the ORR compared
with the results obtained by the regimen DC alone in randomised
phase II studies. The ORR was 41.2% of DC plus cetuximab in the
DOCETUX study, and 18.5 and 26%, respectively, of DC alone in
the SAKK42/99 and V-325 studies. The DC plus cetuximab
treatment achieved the same ORR in both different histotypes,
intestinal and non-intestinal adenocarcinoma. We observed a
trend (not statistically significant) between treatment activity and
the severity of cetuximab-induced skin reactions, as reported in
the other study with cetuximab-based therapy (Cunningham et al,
2004; Jonker et al, 2007; Pinto et al, 2007; Bokemeyer et al, 2009).
An additional finding was that the DC plus cetuximab regimen
resulted in a short time to response (median 6 weeks). This
suggests that this combination may also be a potentially effective
treatment in a neoadjuvant setting, where a rapid tumour
reduction before curative surgery is important. Three patients in
the DOCETUX trial (two with locally advanced disease and 1 with
peritoneal metastases) have obtained remission after treatment
that has permitted radical surgery.
In this study, we have a marginal increase in TTP (5 months)
and lack of improvement in OS (9 months). These OS data may be
the result of the unfavourable characteristics of the patients: 43.1%
with non-intestinal histotype (77.4% with signet ring cells), 95.8%
with metastatic disease, and 76.4% with X2 organs involved.
Furthermore, the median age of the patients was 63 years and 39%
of the patients were X65 years old (higher than the V-325 study
with a median age of 55 years and 24% of patients X65 years old
(Van Cutsem et al, 2006). Although the analysis was not planned,
this study suggests a non-statistically significantly favourable
disease control trend in patients treated with cetuximab main-
tenance compared with patients without maintenance treatment
(TTP 9.2 vs 6.6 months; OS 19.8 vs 7.7 months). The possibly
favourable impact on TTP and OS of cetuximab maintenance
treatment in patients who had at least stable disease after
chemotherapy plus cetuximab therapy was also suggested by the
results of our earlier phase II study in advanced gastric cancer
patients treated with FOLFIRI plus cetuximab (FOLCETUX Study)
(Pinto et al, 2007) and phase III study in recurrent or metastatic
head and neck cancer patients treated with platinum-based
chemotherapy plus cetuximab (EXSTREME Study) (Vermorken
et al, 2008).
The major toxicity of the DOCETUX treatment appears to be
limited to neutropenia (44.4% of grades 3–4, with 19.4% of febrile
neutropenia). Gastrointestinal toxicities (stomatitis, diarrhoea)
were modest (8.4%). Overall, the side effects were moderate. The
toxicity of DC chemotherapy was unaffected by the addition of
cetuximab. The percentage of grades 3–4 neutropenia in the
DOCETUX regimen was lower that in the DC regimen of the
SAKK42/99 study (76% of grades 3–4, with 21% of febrile
neutropenia) and V-325 study (87% grades 3–4, with 27% of
febrile neutropenia). These data could be related to a lower dose of
cisplatin (75mgm2) in the DOCETUX study. The specific side
effects associated with cetuximab were skin reactions (70.8% all
grades, and 16.7% of grades 3–4), infusion-related reactions (2.8%
of grade 3), and hypomagnesemia (62.5% all grades, and 1.4% of
grades 3–4). Compliance with cetuximab was good, with only two
patients (2.8%) discontinuing the treatment for grade 3 infusion-
related reactions. There were no treatment-related deaths.
In the DOCETUX phase II study, cetuximab in combination with
the cisplatin/docetaxel regimen increases the ORR of the cisplatin/
docetaxel doublet and allows for a well-tolerated dose of both
drugs. The lack of improvement in OS could be correlated to the
unfavourable characteristics of the patients, such as the absence of
a fluopyrimidine in the chemotherapy regimen. These results
support new trials in the first-line regimen of advanced gastric or
GEJ adenocarcinoma. Future studies should investigate the major
active chemotherapy triplet with schedules of 5-fluorouracil (or
oral fluopyrimidines) plus cisplatin and docetaxel in combination
with cetuximab under different settings.
REFERENCES
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho
S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-
institutional randomized trial of docetaxel plus cisplatin with or without
fluorouracil in patients with untreated, advanced gastric, or gastro-
esophageal adenocarcinoma. J Clin Oncol 23: 5660–5667
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M,
Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S (2009)
Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-
FU (CF) as first-line therapy in patients with advanced gastric cancer
(FLAGS). Proc ASCO GI, Abstract 8
Cetuximab in combination with cisplatin and docetaxel
C Pinto et al
1266
British Journal of Cancer (2009) 101(8), 1261 – 1268 & 2009 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
Albanell J, Rojo F, Baselga J (2001) Pharmacodynamic studies with the
epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839.
Semin Oncol 28(Suppl 16): 56–66
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de
Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A,
Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol 10: 663–671
Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C (2008)
Cancer mortality in the European Union, 1970–2003, with a joinpoint
analysis. Ann Oncol 19: 631–640
Ciardiello F, Tortora G (2001) A novel approach in the treatment of
cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:
2958–2970
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,
Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E
(2004) Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:
337–345
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, coxon F,
Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal
Clinical Studies Group of the National Cancer Research Institute of the
United Kingdom (2008) Capecitabine and oxaliplatin for advanced
esophagogastric cancer. N Engl J Med 358: 36–46
Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M,
Goker E, Cisar L, Wang K, Bugat R (2008) Randomized phase III study
comparing irinotecan combined with 5-fluorouracil and folinic acid to
cisplatin combined with 5-fluorouracil in chemotherapy naive patients
with advanced adenocarcinoma of the stomach or esophagogastric
junction. Ann Oncol 19(8): 1450–1457
Garcia M, Ward EM, Center MM (2007) Global Cancer Facts and Figures
2007 [online]. Accessed August 20, 2008. URL: www.cancer.gov
Han S, Park R, Lee K, Song H, Kim MA, Oh D, Im S, Kim W, Bang Y, Kim T
(2008) Phase II study and biomarker analysis of cetuximab in
combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line
treatment in patients with recurrent or metastatic gastric cancer. J Clin
Oncol 26: 15S, Proc ASCO, Abstract 4549
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi
IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study
and biomarker analysis of cetuximab combined with modified FOLFOX6
in advanced gastric cancer. Br J Cancer 100: 298–304
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry
SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R,
Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal
cancer. N Engl J Med 357: 2040–2048
Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M,
Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J,
Forster G, McCloud PI (2009) Capecitabine/cisplatin vs 5-fluorouracil/
cisplatin as first-line therapy in patients with advanced gastric cancer:
a randomised phase III noninferiority trial. Ann Oncol 20: 666–673
kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M,
Daum S, Galle P, Moehler MH, AIO Gastric group, Germany (2009)
Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in
advanced gastric cancer: A nonrandomized multicenter AIO phase II
study. Preliminary results of a nonrandomised multi-centre AIO phase II
study. J Clin Oncol 27: 15s, Proc ASCO, Abstract 4534
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete
observation. J Am Stat Assoc 53: 457–481
Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors.
J Clin Epidemiol 56: 1–9
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M,
Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T,
Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1
plus cisplatin versus S-1 alone for first-line treatment of advanced
gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215–221
Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wo¨ll E, Decker T,
Endlicher E, Ro¨thling N, Fend F, Peschel C (2007) Cetuximab plus weekly
oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final
results from a multicenter phase II study of the AIO upper GI study
group. J Clin Oncol 25: 18S, Proc ASCO, Abstract 4526
Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T,
Roethling N, Peschel C, Lordick F (2007) Split-dose docetaxel, cisplatin
and leucovorin/fluorouracil as first-line therapy in advanced gastric
cancer and adenocarcinoma of the gastroesophageal junction: results of a
phase II trial. Ann Oncol 18: 1673–1679
Malvezzi M, Bosetti C, Negri E, La Vecchia C, Decarli A (2008) Cancer
Mortality in Italy, 1970–2002. Tumori 94: 640–657
Mendelsohn J (2002) Targeting the epidermal growth factor receptor for
cancer therapy. J Clin Oncol 20: 1–13
Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G
(2008) Epidermal growth factor receptor structural alterations in gastric
cancer. BMC Cancer 8: 10
Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L (2004) C225
antiepidermal growth factor receptor antibody enhances the efficacy
of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:
1163–1173
National Cancer Institute (NCI) (2006) Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0, 9 August
Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L,
Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F (2006) Weekly
docetaxel and capecitabine is not effective in the treatment of advanced
gastric cancer: a phase II study. Ann Oncol 17: 1529–1532
Park SR, Chun JH, Kim YW, Lee JH, Choi IJ, Kim CG, Lee JS, Bae JM, Kim
HK (2005) Phase II study of lowdose docetaxel/fluorouracil/cisplatin in
metastatic gastric carcinoma. Am J Clin Oncol 28: 433–438
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002.
CA Cancer J Clin 55: 74–108
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C,
Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C,
Piana E, Martoni AA (2007) Phase II study of cetuximab in combination
with FOLFIRI in patients with untreated advanced gastric or gastro-
esophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:
510–517
Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Ko¨berle D, Borner
MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R,
Widmer L, Seymour M, de Braud F, Swiss Group for Clinical Cancer
Research (2007) Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cispla-
tin (TC) versus epirubicin-cisplatin- 5FU (ECF) as systemic treatment for
advanced gastric carcinoma (AGC): a randomized Phase II trial of
the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 25:
3217–3223
Simon R (1989) Optimal two-stages designs for phase II clinical trials.
Control Clin Trials 10: 1–10
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA,
Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J,
Lenz HJ, Borg C, Middleton G, Kro¨ning H, Luppi G, Kisker O,
Zubel A, Langer C, Kopit J, Burris III HA (2008) EPIC: phase III trial
of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin Oncol 26:
2311–2319
Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ
(2007) Tumor growth inhibition with cetuximab and chemotherapy in
non-small cell lung cancer xenografts expressing wild-type and mutated
epidermal growth factor receptor. Clin Cancer Res 13: 1540–1551
Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A
(2003) Expression of epidermal growth factor receptor in gastric
carcinomas. Clin Gastroenterol Hepatol 1: 438–445
Tebbutt N, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D,
Gebski V, Munro S, Cummins M (2007) ATTAX: randomized multicenter
phase III study evaluating weekly docetaxel based chemotherapy
combinations in advanced esophago-gastric cancer, final results of an
AGITG trial. J Clin Oncol 23: 16S, Proc ASCO, Abstract 4528
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumors: European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer Institute
of Canada. J Natl Cancer Inst 92: 205–216
Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama
T, Yoshiyuki T, Nishi K, Matsukura N (1995) Clinical significance of
epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human
gastric cancer. Cancer 75: 1418–1425
Van Cutsem E, Ko¨hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,
D’Haens G, Pinte´r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P,
Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab
and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med 360: 1408–1417
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni
C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Rise ML, Ajani JA, V325
Study Group (2006) Phase III study of docetaxel and cisplatin plus
Cetuximab in combination with cisplatin and docetaxel
C Pinto et al
1267
British Journal of Cancer (2009) 101(8), 1261 – 1268& 2009 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: a report of the V325 Study Group.
J Clin Oncol 24: 4991–4997
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J,
Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M,
Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N,
Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head
and neck cancer. N Engl J Med 359: 1116–1127
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006)
Chemotherapy in advanced gastric cancer: a systematic review and meta-
analysis based on aggregate data. J Clin Oncol 24: 2903–2909
Yeh K, Hsu C, Hsu C, Lin C, Shen Y, Wu S, Chiou T, Chao Y, Cheng A
(2009) Phase II study of cetuximab plus weekly cisplatin and 24-hour
infusion of high-dose 5-fluorouracil and leucovorin for the first-line
treatment of advanced gastric cancer. J Clin Oncol 27: Proc ASCO,
Abstract 4567
Zhang X, Xu J, Shen L, Wang J, Liang J, Xu N, Bai Y, Wang J (2008) A phase
II study of cetuximab (Cetuximab) with cisplatin and capecitabine
(Xeloda) as 1st line treatment in advanced gastric cancer. J Clin Oncol 26:
15S, Proc ASCO, Abstract 15663
Zheng L, Wang L, Ajani J, Xie K (2004) Molecular basis of gastric cancer
development and progression. Gastric Cancer 7: 61–77
Cetuximab in combination with cisplatin and docetaxel
C Pinto et al
1268
British Journal of Cancer (2009) 101(8), 1261 – 1268 & 2009 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
